ANI Pharmaceuticals Inc (NASDAQ:ANIP) Sees Significant Decline in Short Interest

ANI Pharmaceuticals Inc (NASDAQ:ANIP) was the recipient of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 705,700 shares, a decrease of 5.6% from the December 15th total of 747,900 shares. Approximately 7.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 168,500 shares, the days-to-cover ratio is currently 4.2 days.

ANIP has been the topic of a number of analyst reports. BidaskClub cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 7th. ValuEngine upgraded ANI Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, January 7th. Finally, Zacks Investment Research upgraded ANI Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. ANI Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $86.40.

Several hedge funds have recently bought and sold shares of ANIP. Invesco Ltd. boosted its holdings in ANI Pharmaceuticals by 113.9% in the second quarter. Invesco Ltd. now owns 214,240 shares of the specialty pharmaceutical company’s stock valued at $17,611,000 after acquiring an additional 114,084 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of ANI Pharmaceuticals during the third quarter worth about $7,028,000. Nomura Holdings Inc. increased its position in shares of ANI Pharmaceuticals by 34.1% during the second quarter. Nomura Holdings Inc. now owns 375,449 shares of the specialty pharmaceutical company’s stock worth $31,071,000 after acquiring an additional 95,462 shares during the last quarter. Nuveen Asset Management LLC purchased a new stake in shares of ANI Pharmaceuticals during the second quarter worth about $7,071,000. Finally, Man Group plc purchased a new stake in shares of ANI Pharmaceuticals during the third quarter worth about $6,194,000. Institutional investors and hedge funds own 75.26% of the company’s stock.

Shares of ANIP stock traded up $0.14 during mid-day trading on Thursday, hitting $61.14. 354 shares of the company’s stock were exchanged, compared to its average volume of 81,585. ANI Pharmaceuticals has a fifty-two week low of $51.89 and a fifty-two week high of $86.96. The stock has a 50-day simple moving average of $60.57 and a two-hundred day simple moving average of $69.67. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.30. The stock has a market cap of $723.71 million, a price-to-earnings ratio of 13.21 and a beta of 1.95.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Wednesday, November 6th. The specialty pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.20). ANI Pharmaceuticals had a return on equity of 28.28% and a net margin of 7.58%. The business had revenue of $51.30 million for the quarter, compared to analyst estimates of $56.10 million. During the same quarter last year, the business earned $1.29 EPS. ANI Pharmaceuticals’s revenue for the quarter was up 1.2% compared to the same quarter last year. As a group, analysts anticipate that ANI Pharmaceuticals will post 4.58 earnings per share for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Further Reading: Equal Weight Rating

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit